-
Product Insights
Alcohol Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Alcohol Addiction - Drugs In Development, 2023’, provides an overview of the Alcohol Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Opium (Opioid) Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Opium (Opioid) Addiction - Drugs In Development, 2023’, provides an overview of the Opium (Opioid) Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bis-5 in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Lymphoma Drug Details: Bis5 (LB-1410) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NYPRG-101 in Cluster Headache Syndrome (Cluster Headache)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NYPRG-101 in Cluster Headache Syndrome (Cluster Headache) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NYPRG-101 in Cluster Headache Syndrome (Cluster Headache) Drug Details:NYPRG-101 (BOL-148)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Cluster Headache Syndrome (Cluster Headache)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Cluster Headache Syndrome (Cluster Headache) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Cluster Headache Syndrome (Cluster Headache) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986012 in Small-Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986012 in Small-Cell Lung Cancer Drug Details:BMS-986012 is under development for the treatment of solid tumor...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Norovirus [Strains Norwalk Gi.1 +...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPT-155 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPT-155 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPT-155 in Solid Tumor Drug Details: FPT-155 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AL-2846 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-2846 in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-2846 in Prostate Cancer Drug Details: AL-2846 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cobimetinib Fumarate in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cobimetinib Fumarate in Refractory Multiple Myeloma Drug Details:Cobimetinib (GDC-0973 / RG7421...